Journal
Clinical Cancer Research
Publication Date
11-1-2024
Volume
30
Issue
21
First Page
4844
Last Page
4855
Document Type
Open Access Publication
DOI
10.1158/1078-0432.CCR-24-0028
Rights and Permissions
Desai P, Lonial S, Cashen A, Kamdar M, Flinn I, O'Brien S, Garcia JS, Korde N, Moslehi J, Wey M, Cheung P, Sharma S, Olabode D, Chen H, Ali Syed F, Liu M, Saeh J, Andrade-Campos M, Kadia TM, Blachly JS. A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies. Clin Cancer Res. 2024 Nov 1;30(21):4844-4855. doi: 10.1158/1078-0432.CCR-24-0028 This open access article is distributed under the Creative Commons AttributionNonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. ©2024 The Authors; Published by the American Association for Cancer Research
Recommended Citation
Desai, Pinkal; Cashen, Amanda; and et al., "A phase 1 first-in-human study of the MCL-1 inhibitor AZD5991 in patients with relapsed/refractory hematologic malignancies." Clinical Cancer Research. 30, 21. 4844 - 4855. (2024).
https://digitalcommons.wustl.edu/oa_4/4490
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
